Anthera Pharmaceuticals announced the completion of dosing in its Phase 2b study of blisibimod for patients with systemic lupus erythematosus.
The PEARL-SC study is a randomized, double-blind Phase 2b study to evaluate the efficacy, safety, and tolerability of monthly and weekly SC administration of blisibimod in patients with systemic lupus erythematosus. The primary endpoint of the PEARL-SC study is clinical improvement at 24 weeks in an SLE responder index (SRI) – a composite responder index evaluating various patient and physician reported clinical disease activity. In addition, PEARL-SC will provide a series of key secondary subgroup and endpoint analyses which will help guide the design of Phase 3 registration studies and further differentiate blisibimod from currently available therapies.
Blisibimod is a selective peptibody antagonist of the B-cell activating factor (BAFF) cytokine associated with a wide range of B-cell mediated automimmune diseases.
For more information call (510) 856–5600 or visit www.anthera.com.